Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563702 | 0.87 | NTRK1 (0.34) | NTRK1MAP2K1MAPK1ERBB2NTRK3 | |
| SCHEMBL1290531 | 0.76 | KDM4E (0.52) | MAP2K1ERBB2 | |
| SCHEMBL29733448 | 0.76 | KDM4E (0.52) | MAP2K1ERBB2 | |
| SCHEMBL478628 | 0.74 | PDPK1 (0.54) | MAP2K1 | |
| SCHEMBL16617333 | 0.72 | — | — | |
| SCHEMBL2595676 | 0.72 | MAP2K4 (0.30) | — | |
| SCHEMBL1230771 | 0.72 | CYP1A2 (0.40) | — | |
| SCHEMBL11977413 | 0.70 | PDPK1 (0.58) | MAPK1ERBB2NTRK3 | |
| SCHEMBL31621168 | 0.70 | MAP2K4 (0.44) | ERBB2 | |
| SCHEMBL16252839 | 0.70 | MAP2K4 (0.51) | NTRK1MAPK1ERBB2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-15 | — | — | US | disclosed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | disclosed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | NTRK1 2382/4885MAP2K1 3683/4885MAPK1 1547/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | NTRK1 2382/4885MAP2K1 3683/4885MAPK1 1547/4885 |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | NTRK1 2382/4885MAP2K1 3683/4885MAPK1 1547/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | NTRK1 2382/4885MAP2K1 3683/4885MAPK1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.